1
|
Detassis S, Precazzini F, Brentari I, Ruffilli R, Ress C, Maglione A, Pernagallo S, Denti MA. SA-ODG platform: a semi-automated and PCR-free method to analyse microRNAs in solid tissues. Analyst 2024; 149:3891-3899. [PMID: 38994789 DOI: 10.1039/d4an00783b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/13/2024]
Abstract
Over the past two decades, numerous techniques have been developed for analysing microRNAs in body fluids and tissues. However, these techniques still face technical challenges, particularly when compared to well-established techniques for proteins and metabolites. Recently, the ODG platform was introduced, which is an innovative technology that allows for the direct detection and quantification of microRNAs in liquid biopsies without requiring extraction or amplification. This study presents the implementation of the ODG platform within a semi-automated protocol to create the "SA-ODG" platform, enhancing the efficiency and precision of microRNA testing while reducing hands-on time required by laboratory staff. For the first time, the SA-ODG platform has been used to directly quantify microRNAs in solid tissues. The results demonstrate precise analysis of miR-122-5p in mouse liver tissues using SA-ODG. These developments represent a crucial step forward in advancing the field of extraction and amplification-free microRNA detection and quantification.
Collapse
Affiliation(s)
- S Detassis
- OPTOI SRL, Via Vienna 8, 38121, Trento, Italy.
| | - F Precazzini
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy
| | - I Brentari
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy
| | - R Ruffilli
- OPTOI SRL, Via Vienna 8, 38121, Trento, Italy.
| | - C Ress
- OPTOI SRL, Via Vienna 8, 38121, Trento, Italy.
| | - A Maglione
- OPTOI SRL, Via Vienna 8, 38121, Trento, Italy.
| | - S Pernagallo
- DESTINA Genomica SL, Parque Tecnológico de la Salud (PTS), Avenida de la Innovación 1, 18016 Granada, Spain
| | - M A Denti
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy
| |
Collapse
|
2
|
Wang J, Huang J, Hu Y, Guo Q, Zhang S, Tian J, Niu Y, Ji L, Xu Y, Tang P, He Y, Wang Y, Zhang S, Yang H, Kang K, Chen X, Li X, Yang M, Gou D. Terminal modifications independent cell-free RNA sequencing enables sensitive early cancer detection and classification. Nat Commun 2024; 15:156. [PMID: 38168054 PMCID: PMC10761679 DOI: 10.1038/s41467-023-44461-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 12/14/2023] [Indexed: 01/05/2024] Open
Abstract
Cell-free RNAs (cfRNAs) offer an opportunity to detect diseases from a transcriptomic perspective, however, existing techniques have fallen short in generating a comprehensive cell-free transcriptome profile. We develop a sensitive library preparation method that is robust down to 100 µl input plasma to analyze cfRNAs independent of their 5'-end modifications. We show that it outperforms adapter ligation-based method in detecting a greater number of cfRNA species. We perform transcriptome-wide characterizations in 165 lung cancer, 30 breast cancer, 37 colorectal cancer, 55 gastric cancer, 15 liver cancer, and 133 cancer-free participants and demonstrate its ability to identify transcriptomic changes occurring in early-stage tumors. We also leverage machine learning analyses on the differentially expressed cfRNA signatures and reveal their robust performance in cancer detection and classification. Our work sets the stage for in-depth study of the cfRNA repertoire and highlights the value of cfRNAs as cancer biomarkers in clinical applications.
Collapse
Affiliation(s)
- Jun Wang
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Jinyong Huang
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
- College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, Guangdong, China
| | - Yunlong Hu
- Department of Clinical Laboratory, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
| | - Qianwen Guo
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Shasha Zhang
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Jinglin Tian
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Yanqin Niu
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Ling Ji
- Department of Clinical Laboratory, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
| | - Yuzhong Xu
- Department of Clinical Laboratory, People's Hospital of Bao'an Shenzhen, Shenzhen, Guangdong, China
| | - Peijun Tang
- Department of Tuberculosis, The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China
| | - Yaqin He
- Surgical Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
| | - Yuna Wang
- School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China
| | - Shuya Zhang
- School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China
| | - Hao Yang
- Department of Clinical Laboratory, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China
| | - Kang Kang
- College of Medicine, Shenzhen University, Shenzhen, Guangdong, China
| | - Xinchun Chen
- College of Medicine, Shenzhen University, Shenzhen, Guangdong, China
| | - Xinying Li
- Shenzhen Geneups Biotechnology Co., Shenzhen, Guangdong, China
| | - Ming Yang
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China
| | - Deming Gou
- College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China.
| |
Collapse
|
3
|
Raveendran S, Al Massih A, Al Hashmi M, Saeed A, Al-Azwani I, Mathew R, Tomei S. Urinary miRNAs: Technical Updates. Microrna 2024; 13:110-123. [PMID: 38778602 DOI: 10.2174/0122115366305985240502094814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 03/21/2024] [Accepted: 04/03/2024] [Indexed: 05/25/2024]
Abstract
Due to its non-invasive nature and easy accessibility, urine serves as a convenient biological fluid for research purposes. Furthermore, urine samples are uncomplicated to preserve and relatively inexpensive. MicroRNAs (miRNAs), small molecules that regulate gene expression post-transcriptionally, play vital roles in numerous cellular processes, including apoptosis, cell differentiation, development, and proliferation. Their dysregulated expression in urine has been proposed as a potential biomarker for various human diseases, including bladder cancer. To draw reliable conclusions about the roles of urinary miRNAs in human diseases, it is essential to have dependable and reproducible methods for miRNA extraction and profiling. In this review, we address the technical challenges associated with studying urinary miRNAs and provide an update on the current technologies used for urinary miRNA isolation, quality control assessment, and miRNA profiling, highlighting both their advantages and limitations.
Collapse
Affiliation(s)
- Santhi Raveendran
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Alia Al Massih
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Muna Al Hashmi
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Asma Saeed
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Iman Al-Azwani
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Rebecca Mathew
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| | - Sara Tomei
- Omics Core, Integrated Genomics Services (IGS), Research Department, Sidra Medicine, Doha, Qatar
| |
Collapse
|
4
|
Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol 2021; 12:707776. [PMID: 34305614 PMCID: PMC8298863 DOI: 10.3389/fphar.2021.707776] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 06/29/2021] [Indexed: 12/24/2022] Open
Abstract
Ulcerative colitis (UC) is a chronic non-specific inflammatory bowel disease, which usually manifests as abdominal pain, diarrhea and hematochezia. The disease often recurs and is difficult to cure. At present, the pathogenesis is not clear, but it is believed that the disease is caused by a complex interaction among immunity, heredity, environment and intestinal microflora disorders. MicroRNA (miRNA) is endogenous single-stranded non-coding RNA of 17–25 nucleotides (nts). They target the 3'Untranslated Region of a target gene and inhibit or degrade the target gene according to the extent of complementary bases. As important gene expression regulators, miRNAs are involved in regulating the expression of most human genes, and play an important role in the pathogenesis of many autoimmune diseases including UC. Studies in recent years have illustrated that abnormal expression of miRNA occurs very early in disease pathogenesis. Moreover, this abnormal expression is highly related to disease activity of UC and colitis-associated cancer, and involves virtually all key UC-related mechanisms, such as immunity and intestinal microbiota dysregulation. Recently, it was discovered that miRNA is highly stable outside the cell in the form of microvesicles, exosomes or apoptotic vesicles, which raises the possibility that miRNA may serve as a novel diagnostic marker for UC. In this review, we summarize the biosynthetic pathway and the function of miRNA, and summarize the usefulness of miRNA for diagnosis, monitoring and prognosis of UC. Then, we described four types of miRNAs involved in regulating the mechanisms of UC occurrence and development: 1) miRNAs are involved in regulating immune cells; 2) affect the intestinal epithelial cells barrier; 3) regulate the homeostasis between gut microbiota and the host; and 4) participate in the formation of tumor in UC. Altogether, we aim to emphasize the close relationship between miRNA and UC as well as to propose that the field has value for developing potential biomarkers as well as therapeutic targets for UC.
Collapse
Affiliation(s)
- Jing Zhou
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jialing Liu
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Yangyang Gao
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Liwei Shen
- School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Sheng Li
- Center for Health Policy & Drug Affairs Operation Management, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Simin Chen
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
5
|
Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis. Int J Mol Sci 2021; 22:ijms22031176. [PMID: 33503982 PMCID: PMC7865473 DOI: 10.3390/ijms22031176] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/15/2021] [Accepted: 01/22/2021] [Indexed: 12/19/2022] Open
Abstract
Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.
Collapse
|
6
|
Siddika T, Heinemann IU. Bringing MicroRNAs to Light: Methods for MicroRNA Quantification and Visualization in Live Cells. Front Bioeng Biotechnol 2021; 8:619583. [PMID: 33537295 PMCID: PMC7848212 DOI: 10.3389/fbioe.2020.619583] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Accepted: 12/15/2020] [Indexed: 12/12/2022] Open
Abstract
MiRNAs are small non-coding RNAs that interact with their target mRNAs for posttranscriptional gene regulation. Finely controlled miRNA biogenesis, target recognition and degradation indicate that maintaining miRNA homeostasis is essential for regulating cell proliferation, growth, differentiation and apoptosis. Increasingly, miRNAs have been recognized as a potential biomarker for disease diagnosis. MiRNAs can be found in blood, plasma, and tissues, and miRNA expression and activity differ in developmental stages, tissues and in response to external stimuli. MiRNA transcripts are matured from pri-miRNA over pre-miRNA to mature miRNA, a process that includes multiple steps and enzymes. Many tools are available to identify and quantify specific miRNAs, ranging from measuring total miRNA, specific miRNA activity, miRNA arrays and miRNA localization. The various miRNA assays differ in accuracy, cost, efficiency and convenience of monitoring miRNA dynamics. To acknowledge the significance and increasing research interest in miRNAs, we summarize the traditional as well as novel methods of miRNA quantification with strengths and limitations of various techniques in biochemical and medical research.
Collapse
Affiliation(s)
| | - Ilka U. Heinemann
- Department of Biochemistry, The University of Western Ontario, London, ON, Canada
| |
Collapse
|